Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stryker OP-1

This article was originally published in The Gray Sheet

Executive Summary

Orthopedic recombinant human protein European launch is slated for the third quarter following CE mark approval May 17. The device is indicated for treatment of non-union fractures of the tibia of at least nine months duration in skeletally mature patients in cases where previous autograft has failed or use of autograft is not feasible. In the U.S., the firm continues its discussions with FDA after the agency issued a not-approvable letter for the product in January due to insufficient radiographic data (1"The Gray Sheet" Feb. 5, 2001, p. 7)
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT014911

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel